Status:

COMPLETED

REmodelling in Diabetic CardiOmapathy: Gender Response to PDE5i InhibiTOrs

Lead Sponsor:

University of Roma La Sapienza

Conditions:

Diabetic Cardiomyopathy

Diabetes Mellitus Type 2

Eligibility:

All Genders

45-80 years

Phase:

PHASE4

Brief Summary

Pathophysiology of diabetic cardiomyopathy (DCM) is yet unclear and gender differences at baseline and a specific treatment have not been indicated. The investigators already demonstrated the positive...

Detailed Description

DCM is yet unclear and gender differences at baseline and a specific treatment have not been indicated. The study aims to characterize DCM, measuring molecular and neuroendocrine assessment to relate ...

Eligibility Criteria

Inclusion

  • age 45-80 years;
  • Diagnosis of Type 2 Diabetes from at least 3 years;
  • HbA1c \< 10%;
  • normal blood pressure or controlled hypertension;
  • BMI \< 40;
  • SIV ≥ 11 mm men, ≥ 10 women and/or diastolic dysfunction (PW-doppler and TDI)

Exclusion

  • current use of PDE5 inhibitors;
  • congenital or valvular cardiomyopathy;
  • ischemic heart disease;
  • proliferative retinopathy;
  • contraindications to tadalafil use (hypersensitivity to tadalafil, nitrates use, severe cardiovascular disorders such as unstable angina or severe heart failure, severe hepatic impairment, blood pressure \<90/50 mmHg, recent history of stroke or myocardial infarction and known hereditary degenerative retinal disorders such as retinitis pigmentosa);
  • contraindications to CMR imaging with mdc (patients with implant such as cardiac pacemakers, insulin pumps, neurostimulators and cochlear implants, or metallic fragments, clips or devices, or severe renal failure with GFR \< 30mL/min/1.73 m2);
  • cronic or acute atrial fibrillation.

Key Trial Info

Start Date :

May 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2019

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT01803828

Start Date

May 1 2014

End Date

July 1 2019

Last Update

July 10 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Dipartimento di Medicina Sperimentale - Sezione di Fisiopatologia Medica - Sapienza Università di Roma

Rome, Italy, 00161

REmodelling in Diabetic CardiOmapathy: Gender Response to PDE5i InhibiTOrs | DecenTrialz